Key facts
- This page summarizes David R. Keefer's Form 4 filing for Virios Therapeutics, Inc. (DWTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Jan 2022, 14:12.
David R. Keefer - 04 Jan 2022 Form 4 Insider Report for Virios Therapeutics, Inc. (DWTX)
- Reporting relationship
- Director
- Issuer ticker
- DWTX
- Reported as of
- 04 Jan 2022
- Net transaction value
- +$28,975
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2022, 14:12:06 UTC
- Prior SEC filing
- 23 Jun 2021
- Next SEC filing
- 30 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Greg Duncan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David R. Keefer filed Form 4 for Virios Therapeutics, Inc. (DWTX) on 05 Jan 2022.
Change
- Previous filing in this sequence was filed on 23 Jun 2021.
- Current net transaction value: +$28,975.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VIRI
transaction
Common Stock
Purchase
- Transaction value
- $28,975
- Shares
- +5,000
- Change %
- Price
- $5.80*
- Shares after
- 5,000
- Date
- 04 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
VIRI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,808
- Date
- 04 Jan 2022
- Ownership
- Ethica Group, LLC
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.75 to $5.80, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
Footnote F2
The securities are owned directly by Ethica Group, LLC ("Ethica"). The Reporting Person is managing member of Ethica and may be deemed to beneficially own the securities held directly by Ethica.